Tuesday, April 9, 2013

Eddingpharm inlicenses marketing rights for Tykerb in China

Eddingpharm, a leading pharmaceuticals marketing company , signed a collaboration agreement with GlaxoSmithKline China that gives Eddingpharm exclusive rights to market and distribute Tykerb in China. Tykerb was recently approved by the SFDA as a treatment for patients with HER2 positive breast cancer. The drug is indicated as a second-line treatment in patients with advanced or metastatic cancer. Terms were not disclosed. 

Eddingpharm focuses on in-licensing, marketing and distributing hospital pharmaceutical products. To date, Eddingpharm has been granted exclusive distribution rights of more than 10 products and achieved outstanding performance on marketed products